Mode
Text Size
Log in / Sign up
Phase 4 Completed N=165 Randomized Triple-blind Treatment

Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

Source: ClinicalTrials.gov NCT00006489 ↗
Enrolled (actual)
165
Serious AEs
7.3%
Results posted
Apr 2017
Primary outcomePrimary: Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV) — 27.1; 30.3; 27.7; 27.5 units on a scale
◆ Published Evidence
Highly cited
262citations · ~20 / year
Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.
JAMA · 2013 · Likely link

Summary

This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a 6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced medication management intervention will accompany all treatment conditions. Follow-up assessments will be completed at 9 and 12 months after treatment.

Linked Publications (4)

  • Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.
    JAMA · 2013 · 262 citations · Likely link
  • Reliability and validity of the PDS and PSS-I among participants with PTSD and alcohol dependence.
    Journal of anxiety disorders · 2012 · 59 citations · Likely link
  • The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving.
    Behaviour research and therapy · 2016 · 23 citations · Open access · Likely link
  • Changes in coping behavior in a randomized controlled trial of concurrent treatment for PTSD and alcohol dependence.
    Behaviour research and therapy · 2017 · 9 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV)
27.1; 30.3; 27.7; 27.5; 15.3; 12.2
PRIMARY
Drinking Timeline Follow-back Interview (TFBI)
75.4; 71.2; 78.6; 74.1; 3.5; 7.3
SECONDARY
Penn Alcohol Cravings Scale
17.7; 17.9; 19.2; 18.7; 8.0; 5.1

Eligibility Criteria

Inclusion Criteria

  • Meets criteria for alcohol dependence and post-traumatic stress disorder.
  • Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per week with at least 1 day of 4 or more drinks).
  • Successfully complete medical detoxification.
  • Exhibit clinically significant trauma-related symptoms.
  • Live in a commutable distance to the University of Pennsylvania and agree to follow-up visits.
  • Aged between 18 and 65 years old.
  • Able to provide an informed consent.
  • Speak and read English.

Exclusion Criteria

  • Current diagnosis of any substance dependence other than alcohol, nicotine, or cannabis.
  • Evidence of opiate use in the past 30 days.
  • Significant risk of violence or history of serious violent behavior during the past year.
  • Continued contact with an intimate partner if assault by the partner is the index trauma.
  • Changes in dosage or medication for any SSRI treatment in the three months prior to entering the study.
  • Unstable or serious medical illness.
  • Current severe psychiatric symptom.
  • Mental retardation or another pervasive developmental disorder.
  • Use of an investigational medication in the past 30 days.
  • Pregnant, nursing or not using reliable contraception.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00006489) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search